This is a binary event and only one of the catalyst for the stock. Investors should take into consideration other catalysts when reviewing the company.

We are also keeping an eye on the upcoming Alzheimer’s Association International Conference in Toronto.
TauRx, which is working on a potential line of treatment to slow the progress
of Alzheimer’s disease. Unlike most previously researched Alzheimer’s
treatments which focussed on Amyloid beta (Aβ) plaques, Dr Claude
Wischik-led TauRx is focussing on Tau-proteins in the brain in his research
for a possible cure. The mid-stage trials for TauRx showed cognitive
benefits to patients taking the drug for 24 and 50 weeks, although with some
dosage-related inconsistencies, which TauRx has tried to fix in the phase-3
trials. TauRx researchers Dr Wischik and Dr Serge Gauthier are registered
to present on the phase 3 trial updates for two separate disease variants –
1) mild to moderate Alzheimers’ disease and 2) behavioural variant
Frontotemporal Dementia (bvFTD) respectively.